Drug Profile
Apabetalone - Resverlogix Corporation
Alternative Names: RVX-000222; RVX-208Latest Information Update: 28 Nov 2023
Price :
$50
*
At a glance
- Originator Resverlogix Corporation
- Class Anti-inflammatories; Antidementias; Antihyperlipidaemics; Antihypertensives; Antiretrovirals; Antivirals; Cardiovascular therapies; Ethers; Ketones; Nootropics; Quinazolines; Small molecules; Urologics; Vascular disorder therapies
- Mechanism of Action Bromodomain and extraterminal domain protein inhibitors; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - COVID 2019 infections
Highest Development Phases
- Phase III Acute coronary syndromes; Atherosclerosis; Low HDL cholesterol; Vascular dementia
- Phase II/III COVID 2019 infections
- Phase II Prediabetic state
- No development reported Alzheimer's disease; Fabry's disease; HIV infections; Pulmonary arterial hypertension; Renal failure
Most Recent Events
- 18 Nov 2023 Resverlogix terminates a phase II/III trial in COVID-2019 infections (Adjunctive treatment) in Brazil and Canada (PO), due to unable to recruit patients (NCT04894266)
- 25 Aug 2023 Pharmacodynamics data from a preclinical studies in Cardiometabolic disease presented at the at the Annual Congress of the European Society of Cardiology (ESC-Card-2023)
- 28 Apr 2023 No recent reports of development identified for preclinical development in Fabry's-disease in Canada (PO)